Ourania Tatsis, EVP, Chief Reg. & Quality Officer at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 4,647 shares at $299.88 ($1.4M) on 2023-02-13, disclosed to the SEC on 2023-02-14.
Scheduled sale ($1.4M) by EVP, Chief Reg. & Quality Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $294.33 | 1,377 | $405K | 29.4% |
| 2 | $295.84 | 2 | $592 | 0.0% |
| 3 | $298.11 | 78 | $23K | 1.7% |
| 4 | $298.26 | 2,995 | $893K | 64.7% |
| 5 | $298.98 | 120 | $36K | 2.6% |
| 6 | $299.88 | 64 |
| $19K |
| 1.4% |
| 7 | $300.79 | 11 | $3K | 0.2% |
| Total | $297.14 avg | 4,647 | $1.4M | 100% |
| Filing → |
| VRTX | SELL | 2026-02-19 | $472K | — | Filing → |
| VRTX | SELL | 2026-02-18 | $750K | — | Filing → |
| VRTX | SELL | 2026-02-12 | $215K | — | Filing → |